Manifesto on inhaled triple therapy in asthma: an Interasma (Global Asthma Association – GAA) document

References

• Tiotiu A, Novakova P, Baiardini I, Bikov A, Chong-Neto H, de-Sousa JC, Emelyanov A, Heffler E, Fogelbach GG, Kowal K, et al. Manifesto on united airways diseases (UAD): an Interasma (global asthma association - GAA) document. J Asthma. 2021;1–16. doi:10.1080/02770903.2021.1879130.
   PubMed Web of Science ®Google Scholar
• Lala A, Ravichandran AK, Chien CV, Garan AR, D’Souza B, Tong MZ, Srivastava A, Herr JJ, Yoo D, Cole RT, et al. A manifesto of collaborative longitudinal cardiovascular care in heart failure. Heart Fail Rev. 2020;25(6):1089–1097. doi:10.1007/s10741-020-10025-1.
   PubMed Web of Science ®Google Scholar
• Cardoso F, MacNeill F, Penault-Llorca F, Eniu A, Sardanelli F, Nordström EB, Poortmans P. Why is appropriate healthcare inaccessible for many European breast cancer patients? - The EBCC 12 manifesto. Breast. 2021;55:128–135. doi:10.1016/j.breast.2020.12.010.
   PubMed Web of Science ®Google Scholar
• Vernooij-Dassen M, Moniz-Cook E, Verhey F, Chattat R, Woods B, Meiland F, Franco M, Holmerova I, Orrell M, de Vugt M. Bridging the divide between biomedical and psychosocial approaches in dementia research: the 2019 INTERDEM manifesto. Aging Ment Health. 2021;25(2):206–212. doi:10.1080/13607863.2019.1693968.
   PubMed Web of Science ®Google Scholar
• Currow DC, Abernethy AP, Fallon M, Portenoy RK. Repurposing medications for hospice/palliative care symptom control is no longer sufficient: a manifesto for change. J Pain Symptom Manage. 2017;53(3):533–539. doi:10.1016/j.jpainsymman.2016.10.358.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention; 2021 [accessed 2021 Sep 12]. https://ginasthma.org/gina-reports/
   Google Scholar
• Charriot J, Maravic M, Huguet M, Vachier I, Suehs C, Bourdin A. "Real-life" management of patients with severe asthma in the biologics era: Can we do better? World Allergy Organ J. 2021;14(4):100528. doi:10.1016/j.waojou.2021.100528.
   PubMed Web of Science ®Google Scholar
• Puggioni F, Brussino L, Canonica GW, Blasi F, Paggiaro P, Caminati M, Latorre M, Heffler E, Senna G, Severe Asthma Network in Italy (SANI) Group. Frequency of tiotropium bromide use and clinical features of patients with severe asthma in a real-life setting: data from the Severe Asthma Network in Italy (SANI) Registry. J Asthma Allergy. 2020;13:599–604. doi:10.2147/JAA.S274245.
   PubMed Web of Science ®Google Scholar
• Averell CM, Laliberté F, Duh MS, Wu JW, Germain G, Faison S. Characterizing real-world use of tiotropium in asthma in the USA. J Asthma Allergy. 2019;12:309–321. doi:10.2147/JAA.S216932.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Fairburn-Beech J, Sato K, Kaise T. Clinical characteristics, treatment patterns, disease burden, and persistence/adherence in patients with asthma initiating inhaled triple therapy: real-world evidence from Japan. Curr Med Res Opin. 2020;36(6):1049–1057. doi:10.1080/03007995.2020.1763937.
   PubMed Web of Science ®Google Scholar
• Hong SH, Cho JY, Kim TB, Lee EK, Kwon SH, Shin JY. Cost-Effectiveness of tiotropium in elderly patients with severe asthma using real-world data. J Allergy Clin Immunol Pract. 2021;9(5):1939–1947.e7. doi:10.1016/j.jaip.2020.11.052.
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Disse B, Schröder-Babo W, Bantje TA, Gahlemann M, Sigmund R, Engel M, van Noord JA. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol. 2011;128(2):308–314. doi:10.1016/j.jaci.2011.04.039.
   PubMed Web of Science ®Google Scholar
• Ohta K, Ichinose M, Tohda Y, Engel M, Moroni-Zentgraf P, Kunimitsu S, Sakamoto W, Adachi M. Long-term once-daily tiotropium Respimat® is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in japan: a randomised, placebo-controlled study. PLoS One. 2015;10(4):e0124109. doi:10.1371/journal.pone.0124109.
   PubMed Web of Science ®Google Scholar
• Buhl R, FitzGerald JM, Meltzer EO, de la Hoz A, Sigmund R, Kerstjens HAM, Bleecker ER. Efficacy of once-daily tiotropium Respimat in adults with asthma at GINA Steps 2-5. Pulm Pharmacol Ther. 2020;60:101881. doi:10.1016/j.pupt.2019.101881.
   PubMed Web of Science ®Google Scholar
• Timmer W, Moroni-Zentgraf P, Cornelissen P, Unseld A, Pizzichini E, Buhl R. Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma. Respir Med. 2015;109(3):329–338. doi:10.1016/j.rmed.2014.12.005.
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, Sigmund R, Seibold W, Moroni-Zentgraf P, Bateman ED. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367(13):1198–1207. doi:10.1056/NEJMoa1208606.
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Moroni-Zentgraf P, Tashkin DP, Dahl R, Paggiaro P, Vandewalker M, Schmidt H, Engel M, Bateman ED. Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. Respir Med. 2016;117:198–206. doi:10.1016/j.rmed.2016.06.013.
   PubMed Web of Science ®Google Scholar
• Doherty DE, Bleecker ER, Moroni-Zentgraf P, Zaremba-Pechmann L, Kerstjens HAM. Tiotropium Respimat efficacy and safety in asthma: relationship to age. J Allergy Clin Immunol Pract. 2020;8(8):2653–2660.e4. doi:10.1016/j.jaip.2020.04.013.
   PubMed Web of Science ®Google Scholar
• Khurana S, Paggiaro P, Buhl R, Bernstein JA, Haddon J, Unseld A, Engel M, Casale TB, Dixon AE. Tiotropium reduces airflow obstruction in asthma patients, independent of body mass index. J Allergy Clin Immunol Pract. 2019;7(7):2425–2428.e7. doi:10.1016/j.jaip.2019.03.007.
   PubMed Web of Science ®Google Scholar
• Casale TB, Bateman ED, Vandewalker M, Virchow JC, Schmidt H, Engel M, Moroni-Zentgraf P, Kerstjens HAM. Tiotropium Respimat add-on is efficacious in symptomatic asthma, independent of T2 phenotype. J Allergy Clin Immunol Pract. 2018;6(3):923–935.e9. doi:10.1016/j.jaip.2017.08.037.
   PubMed Web of Science ®Google Scholar
• Hoshino M, Ohtawa J, Akitsu K. Effects of the addition of tiotropium on airway dimensions in symptomatic asthma. Allergy Asthma Proc. 2016;37(6):147–153. doi:10.2500/aap.2016.37.3991.
   PubMed Web of Science ®Google Scholar
• Hoshino M, Akitsu K, Ohtawa J. Comparison between montelukast and tiotropium as add-on therapy to inhaled corticosteroids plus a long-acting β2-agonist in for patients with asthma. J Asthma. 2019;56(9):995–1003. doi:10.1080/02770903.2018.1514047.
   PubMed Web of Science ®Google Scholar
• Yoshida M, Kaneko Y, Ishimatsu A, Komori M, Iwanaga T, Inoue H. Effects of tiotropium on lung function in current smokers and never smokers with bronchial asthma. Pulm Pharmacol Ther. 2017;42:7–12. doi:10.1016/j.pupt.2016.11.004.
   PubMed Web of Science ®Google Scholar
• Yoshida M, Nakano T, Fukuyama S, Matsumoto T, Eguchi M, Moriwaki A, Takata S, Machida K, Kanaya A, Matsumoto K, et al. Effects of tiotropium on lung function in severe asthmatics with or without emphysematous changes. Pulm Pharmacol Ther. 2013;26(2):159–166. doi:10.1016/j.pupt.2012.09.007.
   PubMed Web of Science ®Google Scholar
• Magnussen H, Bugnas B, van Noord J, Schmidt P, Gerken F, Kesten S. Improvements with tiotropium in COPD patients with concomitant asthma. Respir Med. 2008;102(1):50–56. doi:10.1016/j.rmed.2007.08.003.
   PubMed Web of Science ®Google Scholar
• Zhang L, Huang G, Jin L, Han S. Therapeutic effects of a long-acting cholinergic receptor blocker, tiotropium bromide, on asthma. Med Sci Monit. 2018;24:944–950. doi:10.12659/MSM.907950.
   PubMed Web of Science ®Google Scholar
• Lee LA, Bailes Z, Barnes N, Boulet LP, Edwards D, Fowler A, Hanania NA, Kerstjens HAM, Kerwin E, Nathan R, et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2021;9(1):69–84. Erratum in: Lancet Respir Med. 2021 Jan 4. doi:10.1016/S2213-2600(20)30389-1.
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Hozawa S, Sagara H, Ohbayashi H, Lee LA, Crawford J, Tamaoki J, Nishi T, Fowler A. Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study. Curr Med Res Opin. 2021;37(9):1657–1665. doi:10.1080/03007995.2021.1944849.
   PubMed Web of Science ®Google Scholar
• Hozawa S, Ohbayashi H, Tsuchiya M, Hara Y, Lee LA, Nakayama T, Tamaoki J, Fowler A, Nishi T. Safety of once-daily single-inhaler triple therapy with fluticasone furoate/umeclidinium/vilanterol in Japanese patients with asthma: a long-term (52-week) phase III open-label study. J Asthma Allergy. 2021;14:809–819. doi:10.2147/JAA.S305918.
   PubMed Web of Science ®Google Scholar
• Yang S, Lee LA, Sule N, Fowler A, Peachey G. Population pharmacokinetic modeling of fluticasone furoate, umeclidinium bromide, and vilanterol in patients with asthma, using data from a phase IIIA study (CAPTAIN). Clin Pharmacokinet. 2021;60(7):887–896. doi:10.1007/s40262-021-00988-1.
   PubMed Web of Science ®Google Scholar
• Virchow JC, Kuna P, Paggiaro P, Papi A, Singh D, Corre S, Zuccaro F, Vele A, Kots M, Georges G, et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019;394(10210):1737–1749. doi:10.1016/S0140-6736(19)32215-9.
   PubMed Web of Science ®Google Scholar
• Singh D, Virchow JC, Canonica GW, Vele A, Kots M, Georges G, Papi A. Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER. Respir Res. 2020;21(1):285. doi:10.1186/s12931-020-01558-y.
   PubMed Web of Science ®Google Scholar
• Papi A, Virchow JC, Singh D, Kots M, Vele A, Georges G, Canonica GW. Extrafine triple therapy and asthma exacerbation seasonality: TRIMARAN and TRIGGER post hoc analyses. J Allergy Clin Immunol. 2021;148(1):262–265.e2. doi:10.1016/j.jaci.2021.01.007.
   PubMed Web of Science ®Google Scholar
• Singh D, Virchow JC, Canonica GW, Vele A, Kots M, Georges G, Papi A. Extrafine triple therapy in patients with asthma and persistent airflow limitation. Eur Respir J. 2020;56(3):2000476. doi:10.1183/13993003.00476-2020.
   PubMed Web of Science ®Google Scholar
• Kerstjens HAM, Maspero J, Chapman KR, van Zyl-Smit RN, Hosoe M, Tanase AM, Lavecchia C, Pethe A, Shu X, D’Andrea P. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium v ersus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med. 202; 8(10):1000–1012. doi:10.1016/S2213-2600(20)30190-9.
   Google Scholar
• Sagara H, Barbier N, Ishii T, Yoshisue H, Nikolaev I, Hosoe M, Gon Y. Efficacy of one time per day, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population. BMJ Open Resp Res. 2021;8(1):e000856. doi:10.1136/bmjresp-2020-000856.
   PubMed Web of Science ®Google Scholar
• Gessner C, Kornmann O, Maspero J, van Zyl-Smit R, Krüll M, Salina A, Gupta P, Bostel S, Fucile S, Conde LG, et al. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: a randomised, Phase IIIb, non-inferiority study (ARGON) with history of one or more exacerbations in previous year. Respir Med. 2020;170:106021. doi:10.1016/j.rmed.2020.106021.
   PubMed Web of Science ®Google Scholar
• Scosyrev E, van Zyl-Smit R, Kerstjens H, Gessner C, Kornmann O, Jain D, Aubrun E, D’Andrea P, Hosoe M, Pethe A, et al. Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials. Respir Med. 2021;180:106311. doi:10.1016/j.rmed.2021.106311.
   PubMed Web of Science ®Google Scholar
• Watz H, Hohlfeld JM, Singh D, Beier J, Diamant Z, Liu J, Hua S, Abd-Elaziz K, Pinot P, Jones I, et al. Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study. Respir Res. 2020;21(1):87. doi:10.1186/s12931-020-01349-5.
   PubMed Web of Science ®Google Scholar
• Beier J, Watz H, Diamant Z, Hohlfeld JM, Singh D, Pinot P, Jones I, Tillmann HC. Lung function improvements following inhaled indacaterol/glycopyrronium/mometasone furoate are independent of dosing time in asthma patients: a randomised trial. ERJ Open Res. 2021;7(2):00425-2020. doi:10.1183/23120541.00425-2020.
   PubMedGoogle Scholar
• Ishiura Y, Fujimura M, Ohkura N, Hara J, Kasahara K, Ishii N, Sawai Y, Shimizu T, Tamaki T, Nomura S. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate improves inspiratory capacity in patients with asthma-chronic obstructive pulmonary disease overlap. COPD. 2020;15:269–277. doi:10.2147/COPD.S231004.
   Google Scholar
• Kew KM, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev. 2016:CD011721.
   PubMed Web of Science ®Google Scholar
• Sobieraj DM, Baker WL, Nguyen E, Weeda ER, Coleman CI, White CM, Lazarus SC, Blake KV, Lang JE. Association of inhaled corticosteroids and long-acting muscarinic antagonists with asthma control in patients with uncontrolled, persistent asthma: a systematic review and meta-analysis. JAMA. 2018;319(14):1473–1484. doi:10.1001/jama.2018.2757.
   PubMed Web of Science ®Google Scholar
• Kim LHY, Saleh C, Whalen-Browne A, O’Byrne PM, Chu DK. Triple vs dual inhaler therapy and asthma outcomes in moderate to severe asthma: a systematic review and meta-analysis. JAMA. 2021;325(24):2466–2479. doi:10.1001/jama.2021.7872.
   PubMed Web of Science ®Google Scholar